Claims
- 1. A method of treatment of obstructive respiratory diseases by inhalative administration of a pharmaceutically suitable salt of the enantiomerically pure ester (3R,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
- 2. The method according to claim 1, wherein the pharmaceutically suitable salt is selected from the group consisting of fluoride, chloride, bromide and iodide.
- 3. The method according to claim 1, wherein the (3R, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 96% enantiomeric excess.
- 4. The method according to claim 1, wherein the (3R, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 97% enantiomeric excess.
- 5. The method according to claim 1, wherein the (3R, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 98% enantiomeric excess.
- 6. The method according to claim 1, wherein the (3R, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 7. The method according to claim 1, wherein the (3R, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 8. The method according to claim 1, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 9. The method according to claim 2, wherein the (3R, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 10. The method according to claim 2, wherein the (3R, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 11. The method according to claim 2, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 12. A method of treatment of obstructive respiratory diseases by inhalative administration of a pharmaceutically suitable salt of the enantiomerically pure ester (3S, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
- 13. The method according to claim 12, wherein the pharmaceutically suitable salt is selected from the group consisting of fluoride, chloride, bromide and iodide.
- 14. The method according to claim 12, wherein the (3S, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 96% enantiomeric excess.
- 15. The method according to claim 12, wherein the (3S, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 97% enantiomeric excess.
- 16. The method according to claim 12, wherein the (3S, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 98% enantiomeric excess.
- 17. The method according to claim 12, wherein the (3S, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 18. The method according to claim 12, wherein the (3S, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 19. The method according to claim 12, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 20. The method according to claim 13, wherein the (3S, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 21. The method according to claim 13, wherein the (3S, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 22. The method according to claim 13, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 23. A method of treatment of spasms of smooth muscles by administration of a pharmaceutically suitable salt of an enantiomerically pure ester selected from the group consisting of
(3R, 2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium, ((3S, 2′R)-)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium, (3R, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium, and (3S, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
- 24. The method according to claim 23, wherein the pharmaceutically suitable salt is selected from the group consisting of fluoride, chloride, bromide and iodide.
- 25. The method according to claim 23, wherein said ester has an enantiomeric purity of minimum 96% enantiomeric excess.
- 26. The method according to claim 23, wherein said ester has an enantiomeric purity of minimum 97% enantiomeric excess.
- 27. The method according to claim 23, wherein said ester has an enantiomeric purity of minimum 98% enantiomeric excess.
- 28. The method according to claim 23, wherein said ester is (3R, 2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium.
- 29. The method according to claim 23, wherein said ester is (3S, 2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium.
- 30. The method according to claim 23, wherein said ester is (3R, 2′R)-3-[cyclohexylhydroxyphenylacetyl)Qxy]-1,1-dimethylpyrrolidinium.
- 31. The method according to claim 23, wherein said ester is (3S, 2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium.
- 32. The method according to claim 23, wherein said salt is administered by inhalation.
- 33. The method according to claim 23, wherein said salt is administered by inhalation of an aerosol formulation.
- 34. The method according to claim 23, wherein said salt is administered by inhalation of a dry powder formulation.
- 35. The method according to claim 24, wherein said salt is administered by inhalation of an aerosol formulation.
- 36. The method according to claim 24, wherein said salt is administered by inhalation of a dry powder formulation.
Priority Claims (1)
Number |
Date |
Country |
Kind |
A 1973/96 |
Nov 1996 |
AT |
|
CROSS REFERENCE TO RELATED APPLICATION
[0001] This is a division of U.S. application Ser. No. 09/901,217, filed Jul. 9, 2001, which was a continuation-in-part of application Ser. No. 09/309,960, filed on May 11, 1999, now U.S. Pat. No. 6,307,060.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09901217 |
Jul 2001 |
US |
Child |
10601542 |
Jun 2003 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09309960 |
May 1999 |
US |
Child |
09901217 |
Jul 2001 |
US |